05/26/2026
Olympus has signed a definitive agreement to acquire BioProtect, a medical device manufacturer that develops implant technologies designed to help improve prostate cancer care and enhance patients’ quality of life. By providing consistent and controllable spacing between the prostate and other critical structures, their technologies help patients preserve gastrointestinal, urinary and sexual functions during and after treatment.
This acquisition marks an important expansion of Olympus’ contributions to oncology and urology in line with its corporate strategy to accelerate innovative technologies and focus on patient safety and outcomes.
With prostate cancer being the second most diagnosed form of cancer among men worldwide, this acquisition underscores our commitment to addressing unmet medical needs in cancer care.
🔗 Learn more here: https://www.olympus-global.com/news/2026/nr03020.html